Antibodies pay Toll to improve their therapeutic efficacy: improving antibody-mediated anticancer treatment via co-activation of Fc-receptors and Toll-like receptors

S. Ganzevles, M. Stigter-van Walsum, M. Schilham, K. Tuk, M. van Egmond, R. Leemans, R. Brakenhoff, J. Bakema

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)204-204
JournalEuropean Journal of Immunology
Volume46
Publication statusPublished - Aug 2016

Cite this